May 23, 2018 – San Diego, Calif. — Access Scientific, LLC announced completion of an in vivo study demonstrating the superior anti-thrombotic (i.e., anti-clotting) property of its unique intravascular catheter material, ChronoFlex C® with BioGUARD™ technology.
The study found that ChronoFlex C with BioGUARD demonstrates thrombo-resistance where it matters most — on the surface of the blood vessel. No other catheter material has demonstrated this clinically important effect.
While other catheter manufacturers claim anti-thrombotic properties that reduce thrombus (clot) formation “on the surface of the catheter,” these anti-thrombotic claims cite in vivo or in vitro studies that show diminished thrombus formation solely on the surface of the catheter. This finding is often and mistakenly conflated with deep vein thrombosis (DVT) – a condition known to be associated with high-risk complications like bloodstream infection or blood clot embolization. There is no evidence that thrombo-resistance on the surface of the catheter has any effect on diminishing DVTs in actual patients.
Today’s announcement may serve to explain, at least in part, why Access Scientific’s POWERWAND™ catheters consistently demonstrate fewer DVTs and fewer total complications (including bloodstream infections) than other catheters used for similar purposes. “We now know it is not just the POWERWAND atraumatic insertion techniques that allow the vessel lining to remain clean and smooth,” said Steve Bierman MD, the company’s Chief Medical Officer. “It is also the catheter material, ChronoFlex C, and our patented BioGUARD processing, that makes POWERWAND anti-thrombotic both on the catheter surface and on the vessel wall.”
As hospitals continue to face the pressures of Value-Based Purchasing, novel products like POWERWAND offer solutions that both improve patient outcomes and reduce overall costs.
Access Scientific said that in the coming months it will reveal results of another completed study (pending publication). Combined with the current announcement of superior anti-thrombogenicity, this next study demonstrate the value of ChronoFlex C with BioGUARD as the ideal material for a wide variety of indwelling vascular catheters.
I guarantee you this news will make your professional life a whole lot easier and even more gratifying.
All over the world, vascular access specialists are now using ultrasound to help insert peripheral IVs (PIVs). Because of this, central line insertions are often avoided and existing central lines are able to be discontinued. That’s the good news.
The bad news is: the median dwell time of ultrasound guided PIVs is 26 hours, and their failure rate is nearly 50%. Ultrasound-guided PIVs just cannot last, they are too short and made of the wrong material (i.e. polyurethane).
Fortunately, Access Scientific has the solution—POWERWAND™ EDC: The first power-injectable, non-trimmable 6cm extended-dwell, 3Fr catheter, specifically designed for ultrasound-guided peripheral IV access. Like all POWERWANDs, the EDC is made of ChronoFlex™C and inserted using either the XL method (easiest) or the accelerated Seldinger technique (fastest).
Does it perform? Preliminary data from a prestigious urban hospital—currently in the process of publishing these remarkable results—revealed the POWERWAND™ EDC average dwell time of 11.2 days. That’s longer than the vast majority of midlines! And, the POWERWAND™ EDC resulted in a 39.1% reduction of central line usage. No other peripheral IV in the world can boast such extraordinary results.
Imagine not having to go back again and again to the same patient to start and restart an ultrasound-guided PIV. Imagine not having to ultimately start a PICC or CVC and risk a CLABSI on that poor patient. Imagine the patient and family sincerely offering you their thanks.
There is a new and better tool in your toolbox—the revolutionary 6cm, 3Fr POWERWAND™ EDC. I’m sure if you try it, you’ll quickly realize it is by far the best peripheral vascular access device ever made.
Steve Bierman MD
Customers often ask, Why does the POWERWAND™ have so many fewer complications than the other midlines and extended-dwell catheters we have tried? Flip that over and it sounds like: Why do other non-POWERWAND midlines have so many more complications (DVTs, leaking, phlebitis, etc.) than POWERWAND midlines?
The answer is really quite simple: Cut catheters appear to cause irritation to the vessel lining (i.e., the intima), which in turn causes complications. Watch this video which depicts the dangers of cut catheters quite well.
The POWERWAND is not a cut catheter; its tip is thermoformed into an atraumatic ZERO-EDGE™ transition. Beyond that, the POWERWAND guidewire has a soft, plastic domed tip. Atraumatic POWERWAND insertion leads to superior clinical outcomes.
But there is more. The other midlines are all made of polyurethane or a polyurethane blend. Those polyurethane midlines with published outcome data all have higher bloodstream infection rates than POWERWAND. Why? Because the POWERWAND is not polyurethane. It is made of a remarkable new polymer called ChronoFlex C®, which before becoming a POWERWAND, goes through our proprietary manufacturing process. The result: Over 20,000 catheter-days of peer-reviewed, published studies, from 5 different investigators and 6 different institutions, with ZERO bloodstream infections.
Atraumatic insertion + Thermoformed ChronoFlex C = The undisputed best-in-class, POWERWAND midline and extended-dwell catheter. There is method to the POWERWAND magic.
Our hearts go out to all the children whose childhoods are interrupted by hospitalization. Thankfully, there is a new and simple way to lessen their suffering—a unique vascular access device that finally offers hospitalized children the true potential for a ONE-STICK hospitalization. That wonderful addition to our vascular access toolbox is the 3Fr Pediatric POWERWAND™.
Children’s wards and Children’s Hospitals all over the country are celebrating the advent of this new, all-purpose Pediatric POWERWAND for its extraordinary first-attempt success rate, superb blood-drawability, extended dwell times (up to 29 days) and minimal complications. As an accomplished pediatric vascular specialist in the Midwest recently said, “It’s so nice to have mothers actually squeezing our hands and thanking us. One told me the POWERWAND prevented her child from getting between 40-50 needlesticks.”
If your facility is a participant in the Children’s Hospitals Solutions for Patient Safety, you’ll be especially happy to learn that the Pediatric POWERWAND addresses 4+1 of the SPS Focus Goals. Used in conjunction with the Pediatric ZPad™ securement device and catheter cushion (which comes in the POWERWAND Pediatric kit, along with several other special accessories), the Pediatric POWERWAND is designed to reduce: (1) CLABSI, (2) Venous Thromboembolism, (3) PIVIEs (infiltrations and extravasations), (4) pressure injuries–PLUS (5) medical adhesive-related skin injuries.
The world of Pediatric vascular access just changed dramatically for the better. The Pediatric POWERWAND—giving hospitalized children their first true shot at a ONE-STICK hospitalization.
I am confident this new POWERWAND product will add greatly to the daily gratification of your important work.
Steve Bierman, MD